Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models

Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae Hoon Kim, Young Tae Kim, Eun Ji Nam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients. Materials and Methods Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity. Results Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patients who underwent non-optimal (residual disease ≥ 1 cm) primary or interval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers. Conclusion Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments.

Original languageEnglish
Pages (from-to)956-963
Number of pages8
JournalCancer Research and Treatment
Volume50
Issue number3
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Heterografts
Neoplasms
Disease-Free Survival
Germ-Line Mutation
Ovarian epithelial cancer
Gynecology
Obstetrics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Eoh, Kyung Jin ; Chung, Young Shin ; Lee, So Hyun ; Park, Sun Ae ; Kim, Hee Jung ; Yang, Wookyeom ; Lee, In Ok ; Lee, Jung Yun ; Cho, Hanbyoul ; Chay, Doo Byung ; Kim, Sunghoon ; Kim, Sang Wun ; Kim, Jae Hoon ; Kim, Young Tae ; Nam, Eun Ji. / Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 3. pp. 956-963.
@article{8a9220bb93494811b91ff511bee5f353,
title = "Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models",
abstract = "Purpose Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients. Materials and Methods Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity. Results Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patients who underwent non-optimal (residual disease ≥ 1 cm) primary or interval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers. Conclusion Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments.",
author = "Eoh, {Kyung Jin} and Chung, {Young Shin} and Lee, {So Hyun} and Park, {Sun Ae} and Kim, {Hee Jung} and Wookyeom Yang and Lee, {In Ok} and Lee, {Jung Yun} and Hanbyoul Cho and Chay, {Doo Byung} and Sunghoon Kim and Kim, {Sang Wun} and Kim, {Jae Hoon} and Kim, {Young Tae} and Nam, {Eun Ji}",
year = "2018",
month = "7",
day = "1",
doi = "10.4143/crt.2017.181",
language = "English",
volume = "50",
pages = "956--963",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "3",

}

Eoh, KJ, Chung, YS, Lee, SH, Park, SA, Kim, HJ, Yang, W, Lee, IO, Lee, JY, Cho, H, Chay, DB, Kim, S, Kim, SW, Kim, JH, Kim, YT & Nam, EJ 2018, 'Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models', Cancer Research and Treatment, vol. 50, no. 3, pp. 956-963. https://doi.org/10.4143/crt.2017.181

Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models. / Eoh, Kyung Jin; Chung, Young Shin; Lee, So Hyun; Park, Sun Ae; Kim, Hee Jung; Yang, Wookyeom; Lee, In Ok; Lee, Jung Yun; Cho, Hanbyoul; Chay, Doo Byung; Kim, Sunghoon; Kim, Sang Wun; Kim, Jae Hoon; Kim, Young Tae; Nam, Eun Ji.

In: Cancer Research and Treatment, Vol. 50, No. 3, 01.07.2018, p. 956-963.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models

AU - Eoh, Kyung Jin

AU - Chung, Young Shin

AU - Lee, So Hyun

AU - Park, Sun Ae

AU - Kim, Hee Jung

AU - Yang, Wookyeom

AU - Lee, In Ok

AU - Lee, Jung Yun

AU - Cho, Hanbyoul

AU - Chay, Doo Byung

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, Jae Hoon

AU - Kim, Young Tae

AU - Nam, Eun Ji

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients. Materials and Methods Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity. Results Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patients who underwent non-optimal (residual disease ≥ 1 cm) primary or interval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers. Conclusion Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments.

AB - Purpose Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients. Materials and Methods Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity. Results Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patients who underwent non-optimal (residual disease ≥ 1 cm) primary or interval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers. Conclusion Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments.

UR - http://www.scopus.com/inward/record.url?scp=85049777976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049777976&partnerID=8YFLogxK

U2 - 10.4143/crt.2017.181

DO - 10.4143/crt.2017.181

M3 - Article

C2 - 29059719

AN - SCOPUS:85049777976

VL - 50

SP - 956

EP - 963

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 3

ER -